UK-18892, a New Aminoglycoside: An In Vitro Study

AUTOR(ES)

Wise, R.

RESUMO

UK-18892 is a new aminoglycoside antibiotic, a derivative of kanamycin A structurally related to amikacin. It was found to be active against a wide range of pathogenic bacteria, including many gentamicin-resistant strains. The spectrum and degree of activity of UK-18892 were similar to those of amikacin, and differences were relatively minor. UK-18892 was about twice as active as amikacin against gentamicin-susceptible strains of Pseudomonas aeruginosa. Both amikacin and UK-18892 were equally active against gentamicin-resistant strains of P. aeruginosa. There were no appreciable differences in the activity of UK-18892 and amikacin against Enterobacteriaceae and Staphylococcus aureus. Cross-resistance between these two antimicrobials was also apparent.

Documentos Relacionados

• In Vitro Studies with UK-18,892, a New Aminoglycoside Antibiotic
• Cochlear toxicity of butikacin (UK-18,892), a new semisynthetic aminoglycoside antibiotic, in guinea pigs.
• UK-18,892: Resistance to Modification by Aminoglycoside-Inactivating Enzymes
• UK31214, a new aminoglycoside and derivative of kanamycin B.
• In Vitro Studies of Netilmicin, a New Aminoglycoside Antibiotic